SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor is drawing attention after 24-month HOPE-3 open-label extension data for deramiocel, presented at the World Muscle Society congress, showed slower upper-limb functional decline after placebo patients switched to treatment. Many traders view the results as supportive of FDA approval for Duchenne muscular dystrophy, while others question how the FDA will assess the data given ongoing disputes over the statistical analysis plan; the regulatory decision remains uncertain.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

A DEA judges pause of the broader cannabis rescheduling case, while considering whether to add a GAO report on agency procedures to the record, has unsettled MSOS traders and delayed a closely watched Schedule III catalyst. The community is split between concern that the delay could stretch the timeline and erase near-term momentum, and calls that the pause is procedural rather than a rejection of rescheduling and the selloff is a buying opportunity.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Microns fiscal fourth-quarter earnings and guidance are the main focus, with traders weighing AI-driven memory demand and tight DRAM and NAND supply against whether strong results are already priced in and how long the memory boom can last. Bulls expect continued pricing strength and an upbeat outlook, while skeptics warn of a sell-the-news reaction and point to memorys cyclical nature and margin risks.

Fair Isaac Corp. engages in the provision of decision management solutions. It operates through the Software and Scores segments. The Software segment includes pre-configured analytic and decision management solutions designed for a specific type of business need or process. The Scores segment focuses on business-to-business scoring solutions and services, business-to-consumer scoring solutions and services including myFICO solutions for consumers and associated professional services. The company was founded by Bill Fair and Earl Isaac in 1956 and is headquartered in San Jose, CA.

Fair Isaac Corp.

Fair, Isaac Corp.

FICO shares are under pressure after the FHFA opened Fannie Mae and Freddie Mac mortgage pricing to VantageScore alongside FICO, raising concerns that competition could erode FICOs mortgage-scoring market share and pricing power; Rocket Mortgages planned use of VantageScore adds to the concern. Traders are split between seeing a lasting threat to FICOs moat and viewing the selloff as excessive because adoption and its impact remain uncertain, with FICO still deeply embedded in lending.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Traders are focused on anticipated ANKTIVA catalysts, including an FDA decision on its papillary bladder-cancer label expansion, potential broader indications, and international sales growth. Bulls see those developments and reported short interest as fuel for a squeeze, while skeptics cite approval uncertainty, volatile trading, and the lack of a concrete near-term announcement.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda is drawing attention after positive Phase 3 results for HETLIOZ in delayed sleep-wake phase disorder, with the study reportedly meeting its primary endpoint. Traders welcomed the news and after-hours move, while debating whether the gains would hold and speculating about a possible approval.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is drawing attention amid a sharp selloff and concerns that Kalshi and Polymarket are taking wagering share, with prediction-market regulation and pressure across betting stocks adding uncertainty. Bears focus on competition and spending, while bulls point to rising DKeX volume and sportsbook growth as signs the business can compete.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulfs push into AI and high-performance-computing data-center leasing, alongside bullish analyst coverage, is a major focus. Optimists point to its power assets and high short interest, while skeptics cite the sharp pullback, financing sensitivity, and execution risks.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances raised FY2026 revenue outlook, reflecting stronger demand for Amtagvi and Proleukin, is driving the sharp rally and analyst target hikes. Traders are broadly bullish and point to possible short-covering and upcoming lung-cancer data, while others warn of profit-taking, overbought conditions, and potential dilution.

TOSHI

Rising volume and a recovery have renewed focus on TOSHIs attempt to break through repeatedly tested chart resistance after an extended period of range-bound trading. Bulls anticipate a breakout and short squeeze, while skeptics point to repeated rejections and selling pressure; no confirmed fundamental catalyst is evident.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Positive Phase 3 results for Vandas HETLIOZ in delayed sleep-wake phase disorder are driving attention, with traders highlighting that the study met its primary endpoint. The community is largely celebrating the clinical milestone, though some question whether the news will translate into lasting share-price gains.

Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ(tasimelteon) in Delayed Sleep-Wake Phase Disorder

Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ(tasimelteon) in Delayed Sleep-Wake Phase Disorder Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ(tasimelteon) in Delayed Sleep-Wake Phase DisorderPR NewswireWASHINGTON, Sept. 29, 2026Study met its primary...

Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences

Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences PR Newswire WASHINGTON, Sept. 2, 2026 WASHINGTON, Sept. 2, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA...

Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission

Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission PR Newswire...

NEREUS Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.

NEREUS Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C. NEREUS Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C. PR Newswire WASHINGTON, Aug. 22, 2026 WASHINGTON, Aug. 22, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc...

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.

Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates

Vanda (VNDA) delivered earnings and revenue surprises of -103.92% and -19.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results

Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results PR Newswire WASHINGTON, Aug. 5, 2026 Fanapt Q2 2026 net product sales increased 23% to $36.0 million; total prescriptions increased 31%Full-year 2026 total revenue...

Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026

Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026 Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026 PR Newswire WASHINGTON, July 29, 2026 Conference Call and Webcast to FollowWASHINGTON, July 29, 2026 /PRNewswire...

Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe

Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab...

NEREUS Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment

NEREUS Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment NEREUS Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment PR Newswire WASHINGTON, July 15, 2026 WASHINGTON, July...

VNDA Stock Gains After-Hours As FDA Grants Rare Pediatric Disease Designation For Experimental Therapy

Equity

Bullish Sentiment

Adding risk (buying more)

Trimming/taking profits

Rotating into safer assets

Staying the course, no changes

We&#39;re about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Stocktwits

We're about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Microsoft Corp

Meta Platforms Inc

SELLAS Life Sciences Group Inc

Alphabet Inc Class A

CoreWeave Inc

SpaceX

Stocktwits Polls

Positive clinical trial data for HETLIOZ triggered significant interest and optimism regarding the stock's future performance.

Traders are highlighting a heavy pipeline of upcoming catalysts, including imminent drug launches and critical FDA decision dates.

Current Price	$5.03
Prev Close	$5.17
Open	$5.17
Dividend Yield	0.00%
50-Day Moving Average	$5.22
Beta	0.82
Avg. Volume	1.02M
PE Ratio	-1.09

52-Week High	$9.94
52-Week Low	$4.27
Market Capitalization	$312.59M
EPS (Annual)	-$3.74
Price to Book	1.38
Revenue Per Employee	$405,450.28

Feed

News

Sentiment

Earnings

Fundamentals

Info

VNDA Fundamentals